New drug targets Hard-to-Treat breast cancer in early trial
Disease control
Not yet recruiting
This study tests a drug called ARX788 for people with HER2-low breast cancer that has spread or cannot be removed by surgery. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The trial will enroll 36 adults to see if the d…
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 15, 2026 11:56 UTC